IFF showcases excipient expertise at CPhI Frankfurt

IFF’s Pharma Solutions is showcasing best-in-class cellulosic excipient expertise, including leading brands like Avicel® and METHOCEL™ at CPhI.

IFF’s Pharma Solutions division is backed by 300 years of combined cellulosic excipient experience. It is home to leading brands like Avicel^® and METHOCEL™ and developed a robust seaweed-based excipient portfolio.

The division is at CPhI Frankfurt this week to showcase its technical expertise, commitment to customers and investment in its team, technology and manufacturing network. From 1 to 3 November, experts will detail how IFF delivers pharmaceutical, dietary supplement and biotechnology solutions through its innovative application support and robust supply chain.

“IFF remains focused on addressing customers’ formulation and manufacturing challenges with real-time solutions that meet their needs,” said Angela Strzelecki, president, Pharma Solutions, IFF. “Our rich legacy as a leader in polymer design and material science allows us to further tailor solutions to each customer in a number of specific market segments and functional excipients.”

Industry-leading products and expertise

At stand 80D100, attendees to CPhI Frankfurt can explore highly customised excipient solutions to address their current formulation challenges, learn cost-effective manufacturing strategies and dive deeper into formulating for highly differentiated consumer trends and demographics.

IFF’s recently appointed director of global quality, Tisha Cromwell will discuss her data-driven approach to quality, which will support IFF in its continual investments in innovation, facilities, processes and people.

“We’re focused on building trust-based relationships with customers, engaging in future innovations and providing answers at every turn, allowing our customers to focus on what they do best and ensure high-quality standards are met at every step of the manufacturing process,” said Cromwell.

Investment boosts capacity and supply

Pharmaceutical customers around the world can expect increased speed to market, enhanced capacity and expanded supply of tablet binders and colloidal excipients, thanks to IFF’s recent multimillion-dollar strategic investment in the Pharma Solutions division’s technology, team and manufacturing network. 

Such investment includes:  

• EXCiPACT certification, independent audit for demonstrated credibility in suitable GMP/GDP standards.
• Greater technical service to customers around the globe, through strengthening our Application Development and Innovation (AD&I) teams. IFF’s global AD&I teams support customers by troubleshooting and optimising their formulation development process. The global footprint now includes state-of-the-art labs in Hyderabad and Mumbai, India; Shanghai, China; Wilmington, US; and Bomlitz, Germany.
• Investments in people, equipment, systems, processes and facilities to support capacity growth.
• Increased global R&D Investment, further strengthening the company’s legacy of innovation, adding technology and capabilities at the Innovation Centre in Bomlitz, Germany.
• Active participation in the International Pharmaceutical Excipients Council (IPEC), allowing IFF to anticipate solutions to future customer challenges.

In addition, IFF continues to emphasise its capabilities in tailoring dietary supplement formulations. Product experts will be onsite at CPhI to discuss existing and emerging challenges in this space, brainstorm solutions and provide insight into industry-leading products, capabilities and expertise to enhance the consumer experience. Manufacturers looking to control the release of an active ingredient, craft a convenient on-the-go format or develop a vegan gummy can learn more about IFF’s wide variety of finished format capabilities at the event.

Click here to learn more about IFF’s broad portfolio and proven expertise.